Additionally, the DFI analysis showed that TAGLN2 methylation acted as a protective marker in KIRC, PAAD, and THCA patients, whereas a detrimental factor for BLCA and STAD (Figure 4F). This evidence concerns the gene TAGLN2 and gastric adenocarcinoma.